# Phase II Study to Assess Safety, Pharmacokinetics and Efficacy of SL-1002 for Limb Spasticity

> **NCT05311215** · PHASE2 · UNKNOWN · sponsor: **Saol Therapeutics Inc** · enrollment: 32 (estimated)

## Conditions studied

- Spasticity

## Interventions

- **DRUG:** SL-1002
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05311215
- **Lead sponsor:** Saol Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-22
- **Primary completion:** 2023-09
- **Final completion:** 2023-09
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2023-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05311215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05311215, "Phase II Study to Assess Safety, Pharmacokinetics and Efficacy of SL-1002 for Limb Spasticity". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05311215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*